SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:
NGEN), developer of advanced diagnostic products, announced today that it
has been issued four patents by the U.S. Patent and Trademark Office for
inventions related to diabetes and Alzheimer's disease biomarkers. The
current patents are the most recent in a series describing biomarkers
associated with these diseases.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050803/LAW135LOGO )
U.S. Patent No. 7,125, 678, "Protein biopolymer markers predictive of
type II diabetes," U.S. Patent No. 7, 097,989, "Complement C3 precursor
biomarker predictive of type II diabetes," and U.S. Patent No. 7,094,549,
"Fibronectin biopolymer marker indicative of insulin resistance," relate to
the use of mass spectrometry and time-of-flight detection to identify
biopolymers that characterize type II diabetes. These markers could
potentially be used in applications of disease risk assessment and
development of therapeutic avenues.
In addition, U.S. Patent No. 7,101,680 "Method for detecting the
presence of monomeric brain associated human glutamine synthetase," relates
to a method for detecting a biochemical marker, human glutamine synthetase,
by immunoassay as a potential diagnostic for Alzheimer's disease. In
addition, a method for distinguishing between AD and non-AD dementia is
For information about licensing opportunities, contact Nanogen.
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and
physicians worldwide with improved methods and tools to predict, diagnose,
and ultimately help treat disease. The company's products include real-time
PCR reagents, the NanoChip(R) electronic microarray platform and a line of
rapid diagnostic tests. Nanogen's ten years of pioneering research
involving nanotechnology holds the promise of miniaturization and continues
to be supported for its potential for diagnostic and biodefense
applications. For additional information please visit Nanogen's website at
This press release contains forward-looking statements that are subject
to risks and uncertainties that could cause actual results to differ
materially from those set forth in the forward-looking statements,
including whether patents owned or licensed by Nanogen will be developed
into products, whether the patents owned by Nanogen offer any protection
against competitors with competing technologies, whether products under
development can be successfully developed and commercialized, whether
results reported by our customers or partners can be identically
replicated, and other risks and uncertainties discussed under the caption
"Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or
Form 10-Q most recently filed with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof. Nanogen
disclaims any intent or obligation to update these forward-looking
SOURCE Nanogen, Inc.